Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study

ConclusionThese results further extend our knowledge of the effectiveness, specifically regarding improvements in cognitive processing speed, disability and PROs, of long-term natalizumab treatment in early RRMS patients.Clinicaltrials.govNCT01485003 (5 December 2011)

http://link.springer.com/10.1007/s40263-022-00950-0

Source: CNS Drugs - September 5, 2022 Category: Neurology Source Type: research